A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death The transmission of viral and non-viral infectious pathogens continues to be the most serious of the potential adverse effects of allogenic tissue transplantations. EU Directive 2006/17/EC stipulates that cadaveric blood specimens for serology testing in the context of post-mortem tissue donation must be taken not later than 24 h post-mortem. An expanded time slot would significantly improve the availability of tissue donations, but there are no significant data on the stability of infectious serology assays for anti-human immunodeficiency virus (HIV), anti-hepatitis C virus (HCV), hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HBC core antigen (HBc) in samples collected more than 24 h post-mortem. In this prospective study, serum samples of 30 deceased persons were taken upon admission to the Institute of Forensic Medicine (University Hospital Hamburg-Eppendorf, Germany) and at 12, 24, 36 and 48 h post-mortem. All samples were measured twice, first using the Abbott AxSYM system, and then after~9 months of storage at "70 6C using the BEP III System with Siemens and Ortho reagents. For HIV, six deceased persons with a pre-mortem HIV history were included. All samples (at committal and at 12, 24, 36, 48 h) were reactive. Indeterminate or false-negative results did not occur. For HCV, 17 deceased persons with a pre-mortem HCV history were included; 16 samples were reactive up to 48 h and one was reactive at 36 h post-mortem (48 h sample was not available). Indeterminate or falsenegative results did not occur. For HBV, nine deceased persons were included: five samples were initially positive for HBsAg and remained positive up to 48 h, and eight of the samples were reactive for anti-HBc up to 48 h and one up to 36 h post-mortem (48 h sample was not available). Indeterminate or false-negative results did not occur. These data suggest that infectious serological testing may be extended for blood samples of potential tissue donors collected up to 48 h post-mortem to detect antibodies or antigens for HIV, HBV and HCV.
INTRODUCTION
Tissue from deceased donors, so-called cadaveric donors, is transplanted in a number of clinical areas. The spectrum ranges from musculoskeletal tissues (bone, cartilage, tendons, ligaments and fascia) to corneas to cardiovascular allografts (aortic and pulmonary valve, pericardium, veins and arteries). Every year in Germany, about 30 000-35 000 of these allogenic tissues are transplanted (Federal Ministry of Justice, 2010) . Obtaining the health history of these donors presents a problem, because information is only available from the attending doctors or family members, who are usually not very approachable about such questions at that particular time and may not be aware of socially less acceptable risks. The results of serological and nucleic acid tests on the blood of potential donors who have received multiple transfusions are not reliable because of haemodilution. Investigations have shown that the rates of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infections of tissue donors are lower than those of the normal population but higher than first-time blood donors (Zou et al., 2004) . Similar results were found in a study of 12 415 donors of musculoskeletal tissue in Australia (Yao et al., 2007) . Furthermore, the mean donor : recipient ratio for corneas is 1 : 2, for cardiovascular transplants is 1 : 1 to 1 : 10, and for musculoskeletal tissues is up to 1 : 40.
With the implementation of EU Directives 2004/23/EC and 2006/17/EC (European Union, 2004 Union, , 2006 , basic requirements of viral safety in tissue donation were defined in general. Whilst serological tests for anti-HIV-1/2, anti-HCV, HBV surface antigen (HBsAg), anti-HBV core antigen (HBc) and Treponema pallidum haemagglutination are mandatory, nucleic acid testing for HIV, HBV and HCV is not explicitly required.
Pre-mortem blood samples of cadaveric donors are usually not available, e.g. for donors from forensic medicine institutes (Püschel et al., 1991) . For deceased potential donors from hospitals, pre-mortem blood samples are frequently no longer available or are too old. These samples should not be older than 7 days and need to have been stored at 2-8 u C after centrifugation immediately after sampling. If such pre-mortem samples are not available, post-mortem blood collected up to 24 h post-mortem may be used when drawn in accordance with the applicable directives. If samples within 24 h post-mortem are not available, according to current EU directives, donation may not occur, resulting in a loss of potential donors. Moreover, in unexplained or unnatural deaths, only the time of discovery, but not the legal time of death, is known.
Prospective studies on the behaviour of infectious parameters for HIV, HBV and HCV under post-mortem conditions do not exist at this time. Therefore, the main objective of the following study was to investigate how serological laboratory parameters in post-mortem conditions in HIV-, HBV-or HCV-infected deceased persons changes over time. A post-mortem stability of these parameters up to 48 h could increase the number of possible donors. This would, for example, significantly reduce the waiting list for cornea transplants in Europe.
METHODS
Deceased. The study included deceased persons with a proven or highly probable HIV and/or HBV and/or HCV infection and a control group from cornea donors without these infections. Inclusion was based on the diagnosis documented by a hospital doctor's certificate of death or on information given by the relatives to the emergency doctor in forensic cases.
Before the start of blood sampling, the next of kin were informed and asked for their consent. If a non-natural cause of death was reported on the death certificate, release by the legal authorities was also required before the collection of blood samples. Upon arrival in the forensic medicine department of the UKE, the time of death was determined in accordance with forensic standards, as well as acquisition of the infection history. The deceased were stored for the study duration in the cooling chambers at the Institute of Forensic Medicine, UKE, under monitored temperatures of 2-8 uC.
The study was carried out after examination and approval by the Ethics Committee of the Hamburg Chamber of Physicians (AZ: WF-024/09).
Blood collection and processing. Blood samples were drawn upon delivery and at 12, 24, 36 and 48 h post-mortem. The blood sampling puncture site was disinfected. Subsequently, using sterile TSK Supra hollow needles (2.006100; TSK Laboratory) and sterile 20 ml syringes (BD Discardit), 20 ml whole blood was extracted from peripheral large vessels (femoralis and subclavian artery and/or vein) and transferred into labelled, empty 10 ml test tubes (Harre Co.). In exceptional cases, drawing blood from the heart was necessary. Centrifugation and serum separation were carried out immediately after drawing the blood sample. One part of the serum was then stored at 2-6 uC, and analysed within 12 h in the Institute for Medical Microbiology, Virology and Hygiene at UKE. The second part of the serum was frozen immediately, stored at 280 uC and tested (~9 months later) in the Institute of Transfusion Medicine at the Charité in Berlin, Germany, as controls.
Analysis. In the UKE, testing was performed on the AxSYM system (Abbott Diagnostics) using microparticle enzyme immunoassays. The HIV Ag/Ab Combo kit was used for anti-HIV testing, the HCV version 3.0 kit for anti-HCV, the HBsAg V2 kit for HBsAg and the Core kit for anti-HBc (all from Abbott Diagnostics). In cases of serum volumes that were too small to use in the AxSYM system, microtitre enzyme immunoassays (Ortho HCV 3.0 kit for anti-HCV, Siemens Enzygnost HBsAg 5.0 kit for HBsAg, and Siemens Enzygnost AntiHBc Monoclonal kit for anti-HBc) were used. The tests were performed according to medical laboratory standards, as well as the specifications of the manufacturer. The test laboratory met all the requirements for internal and external quality controls.
In the Charité, tests were performed on the BEP III System (Siemens) using an ELISA test. The test kit Enzygnost Anti-HIV 1/2 Plus (Siemens) was used for anti-HIV, HCV version 3.0 ELISA with Enhanced SAVE (Ortho) for anti-HCV, Enzygnost HBsAg version 6.0 (Siemens) for HBsAg and Enzygnost anti-HBc Monoclonal (Siemens) for anti-HBc. The tests were performed according to medical laboratory standards, as well as the specifications of the manufacturer. The test laboratory met all the requirements for internal and external quality controls.
Statistical analysis. Statistical analysis was performed using software STATA for Windows, version 10 (Stata Corp.). Using a linear regression analysis, the 48 h results were compared with the results of the time points of committal, and 12, 24 and 36 h post-mortem.
RESULTS
Serum samples of 30 deceased persons were analysed, including two individuals with a double infection (HIV/ HCV, HBV/HCV). The mean time between death and delivery time was 5.9 h (minimum 2.0 h, maximum 13.0 h). None of the deceased showed signs of decomposition. All serum samples showed minimal haemolysis macroscopically at 36 h post-mortem and a moderate to severe haemolysis at 48 h post-mortem. The serum samples at committal and 12 h and 24 h post-mortem were macroscopically without pathological findings. For technical or logistical reasons (e.g. low blood volume, delayed approval by the relatives, forensic issues), it was not possible to collect blood from all the deceased at all time points. In addition, the control testing using Siemens and Ortho assays was not in all cases possible.
HIV
A total of six deceased persons (five male, one female) aged 37-61 years were studied. All subjects were anti-HIV positive at the time of the first testing (committal or 12 h post-mortem) ( Table 1 ). In subsequent post-mortem tests up to 48 h, all the findings remained clearly positive. No borderline results were found. All results were confirmed by control testing with the Siemens assay (after 8-10 months in storage at 270 u C).
HCV
A total of 20 deceased persons (14 male, six female) aged 32-81 years were initially selected to be studied. Three cases had to be excluded because the relatives did not give informed consent. The remaining 17 subjects were anti-HCV positive at the time of the first testing (committal, 12 or 24 h post-mortem and in one case 36 h post-mortem) ( Table 2) . Sixteen of these subjects were still anti-HCV positive after 48 h post-mortem. One subject could only be measured up to 36 h post-mortem, because no more samples were available for the 48 h test. The 36 h sample of this subject was positive (Table 2) . No borderline results were found. Control testing with the Ortho assay (after 8-10 months in storage at 270 u C) confirmed the positive results.
HBV
A total of ten deceased persons (six male, four female) aged 32-74 years were initially selected to be studied. One case had to be excluded because the relatives did not give informed consent. In four of the remaining nine subjects, despite a positive history of infection, the test at delivery and all subsequent tests up to 48 h were HBsAg negative. All five of the remaining subjects were HBsAg positive at first testing (committal, or 12 or 24 h postmortem) (Table 3 ). In one subject (no. 4), the 36 and the 48 h samples were tested only with the Siemens assay (after 8-10 months storage at 270 u C) and only the sample taken at 24 h post-mortem was tested in both systems. All five samples remained positive after 48 h. Control testing using the Siemens assay (after 8-10 months in storage at 270 u C) confirmed the positive results.
All nine subjects were positive for anti-HBc at delivery and at all time intervals measured up to 48 h (up to 36 h in one case) (Table 4) . However, control tests performed with the Siemens assay after serum storage at 270 u C for 8-10 months revealed contradictory anti-HBc negative results in five out of 32 samples. These five samples were from two HBsAg-negative subjects. In one case (three samples), primary testing with the AxSYM system had revealed only a lower reactivity for anti-HBc (Table 4 , patient 8).
Control group
There were 12 deceased cornea donors with known negative serology studied. Up to 48 h post-mortem, all results for HIV, HBV and HCV remained as true negatives. No borderline results were found. sample time of 35 h. The sensitivity ranged from 94 to 97 % and the specificity was 99 %. False-positive reactions showed no correlation with haemolysis. Of the 35 HIV-positive donors, 34 were confirmed as true positives, whilst one was shown to be a false negative, even using multiple test systems (Pepose et al., 1987) . The authors attributed this to the existence of a pre-mortem titre reduction in HIV antibodies (Essex et al., 1985) , highlighting the importance of access to the donor's medical history. The same group, in a subsequent study on HBsAg, showed a sensitivity of 92.9 %. The specificity, compared with a radioimmunoassay, was only 81.3 % (409 samples). Laycock et al. (1997) investigated 101 cadaver blood samples from cornea donors from eight cornea banks without explicitly stating the post-mortem time.
From 101 cadavers, 70 tested positive and 31 negative using the HCV EIA version 1.0 test (Abbott Laboratories). They were retested with the Abbott Laboratories HCV EIA version 2.0 test and the Matrix HCV recombinant immunoblot assay as a reference standard. The results showed a sensitivity of 100 % and a specificity of 93 % for the HCV EIA version 2.0 test. Notably, only in three of the 15 HCVpositive sera could the HCV genome be verified (Laycock et al., 1997) . In a study of paired blood samples from cornea donors (33 pre-mortem vs 33 post-mortem samples of the same donors), Heim et al. (1999) found that in 17/33 cases, the results did not match. Of these 17 non-matching cases, 16 were HBsAg post-mortem false positives, and in one case the post-mortem anti-HCV result was a false negative.
Testing of the corresponding pre-mortem serum revealed an anti-HCV-positive result, which was confirmed by a RIBA HCV strip immunoassay. Forensic DNA profiling of both serum samples confirmed that they were derived from the same individual. Although both serum samples from the donor were negative for HCV RNA, the authors propose the use of HCV PCR on cornea donor blood samples (Heim et al., 1999) . Another important study was that of Challine et al. (2006) . A total of 565 cornea donors was systematically tested or examined accordingly for anti-HIV, anti-HCV, HBsAg, anti-HBc and macroscopic changes. The post-mortem sampling interval of all samples was recorded and classified into four groups: ,12, 12-24, 24-36 and .36 h. A direct and significant correlation between the post-mortem blood sampling time and macroscopic abnormal findings (especially haemolysis, and icteric or turbid sera) was described. These, in turn, led to a significant increase in false-positive findings, especially for HBsAg and anti-HIV. At the same time, the rate of retesting was increased due to discrepant results in abnormal macroscopy. However, neither the prevalence of positive results nor their accuracy depended on the post-mortem blood sampling time. The authors concluded that post-mortem blood samples are haemolysed over time, and thus generate discrepant or false-positive results, which leads to retesting, and therefore increasing costs, as well as the discarding of corneae. A significant influence of post-mortem blood sample timing on the accuracy of the results was not found. Due to the high number of falsepositive results and the macroscopic changes in serum, the authors recommended a post-mortem blood drawing time of 12 h maximum.
Several conclusions can be drawn from these publications. The rate of false-positive findings (especially for HBsAg) increases with increasing post-mortem interval. This is due to macroscopically visible changes of the serum/plasma as a result of haemolysis, other types of cell degeneration and, where applicable, bacterial growth. Neither the prevalence of positive results nor the accuracy seems to depend on the postmortem sampling time, even if it is .36 h. However, there were two contradictory findings: one case with a false-negative result was published for anti-HIV and one for anti-HCV.
In our prospective study, we investigated for the first time post-mortem changes in serological parameters for HIV, HBV and HCV up to 48 h in 30 deceased individuals. Contrary to the findings of Challine et al. (2006) and Heim et al. (1999) , we found neither false-positive nor falsenegative results up to 48 h post-mortem, although in all samples we found minimal haemolysis after 36 h postmortem and moderate to severe haemolysis after 48 h postmortem. One reason could be the lower sensitivity of modern EIA test kits to disturbance variables such as haemolysis. Another reason might be the consistent and rigorous pre-analysis, a process that assures blood testing in the shortest possible time as well as storage under standardized conditions. In this respect, a long standing time before centrifugation and delays in sample storing at 2-6 u C should be avoided. Prolonged frozen storage did not affect our test results for HIV, HCV and HBsAg. The laboratory systems (AxSYM and BEP III) used in this study worked reliably and without technical complications.
The implementation of nucleic acid testing for HIV, HBV and HCV could be useful, depending on the type of tissue and their donor : recipient ratio (Pruss et al., 2010) . Finally, to examine samples obtained post-mortem, there are only a few tests that are validated and CE (European Conformity)-recognized. Individual validations for the use of postmortem samples and suitable 'spiking' procedures should be performed as soon as possible, in order to make the diagnostics reliable (Kitchen & Newham, 2011) .
From the perspective of the authors, this study presents evidence to suggest that the time limit for tissue donors specified in EU Directive 2006/17/EC of 24 h post-mortem should be reconsidered and increased to 48 h.
